Our findings establish that regulation of RAS stability by T148 phosphorylation is preferentially active across diverse hematologic malignancies, including MM, AML, and GCB DLBCL, and point to PAK1/2 inhibition as a key therapeutic vulnerability in these cancers. This evidence concerns the gene PAK1 and Miyoshi myopathy.